GMA-301 is under clinical development by Gmax Biopharm and currently in Phase I for Pulmonary Arterial Hypertension. According to GlobalData, Phase I drugs for Pulmonary Arterial Hypertension have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GMA-301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GMA-301 overview

GMA-301 is under development for the treatment of pulmonary arterial hypertension in children and adults. The drug candidate is a recombinant monoclonal antibody. It is administered through intravenous route. The drug candidate is developed based on g-protein-coupled receptor (GPCR) antibody technology platform. It acts by targeting endothelin receptor A (ETaR). It was also under development for the treatment of ovarian cancer and prostate cancer.

Gmax Biopharm overview

Gmax Biopharm is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody and Bibody development, to address the unmet medical needs in cardiovascular diseases, metabolic disorders and cancer. The company is headquartered in Hangzhou, China.

For a complete picture of GMA-301’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.